Welcome to Psynova Neurotech

Psynova Neurotech is exclusively focused on the commercial development and exploitation of novel biomarkers for Neuropsychiatric and other mental illnesses.

Building on 12 years of ground-breaking research by its founder Prof. Sabine Bahn, Psynova Neurotech is initially concentrating on Schizophrenia and Bipolar Affective Disorder.” VeriPsych™ is the first and only blood test to aid a psychiatrist in the diagnosis of recent-onset schizophrenia. For more information visit the VeriPsych™ website.

Press Releases

Date: 03-02-2011

Psynova wins ACES award for Life Sciences

ACES award

Date: 26-09-2011

RBM / Psynova Neurotech Ltd Reaches a Significant Milestone in Companion Diagnostic Program With Roche

Milestone Demonstrates Effectiveness of RBM’s Strategic Biomarker Services
Rules-Based Medicine (RBM), a global leader in biomarker testing services, and its subsidiary, Psynova Neurotech, has achieved a significant milestone in a companion diagnostic development program with Roche. Using samples from a Roche clinical trial, the RBM DiscoveryMAP® platform, and Psynova’s biomarker database and expertise, a biomarker pattern was identified that has utility in prognosis of disease progression and/or predicting or monitoring the efficacy for a compound in the Roche CNS pipeline. Roche has exercised its option to continue commercial development based on these results, which could result in additional future milestone and royalty payments to RBM/Psynova.

“Achieving this milestone is an example of how pharmaceutical and biotechnology companies can leverage RBM’s testing services, databases, and expertise to make real progress,” said Craig Benson, President and CEO of RBM. [more]